Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
4.920
+0.030 (0.61%)
At close: Aug 26, 2026, 4:00 PM EDT
4.920
0.00 (0.00%)
After-hours: Aug 26, 2026, 4:10 PM EDT

Evolent Health Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Evolent Health stock has a consensus rating of "Buy" and an average price target of $5.77. The average 1-year stock price forecast is 17.28% higher than the current stock price, while the lowest is $3.00 (-39.02%) and the highest is $8.00 (+62.60%).

Price Target: $5.77 (+17.28%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$3.00$5.77$6.00$8.00
Change-39.02%+17.28%+21.95%+62.60%

Analyst Ratings

The average analyst rating for Evolent Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy101010868
Buy444444
Hold222343
Sell000000
Strong Sell000000
Total161616151415

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
J.P. Morgan
J.P. Morgan
Buy
Reiterates
$5$6
BuyReiterates$5$6+21.95%Aug 18, 2026
TD Cowen
TD Cowen
Buy
Reiterates
$5$6
BuyReiterates$5$6+21.95%Aug 17, 2026
Truist Financial
Truist Financial
Hold
Reiterates
$7$6
HoldReiterates$7$6+21.95%Aug 12, 2026
Citi
Citi
Buy
Upgrades
$6.75$6
BuyUpgrades$6.75$6+21.95%Aug 10, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$7$6
BuyMaintains$7$6+21.95%Aug 10, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
2.64B
from 1.88B
Increased by 40.50%
Revenue Next Year
3.30B
from 2.64B
Increased by 25.10%
EPS This Year
0.20
from 0.09
Increased by 121.83%
EPS Next Year
0.39
from 0.20
Increased by 95.84%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
907.96M1.35B1.96B2.55B1.88B2.64B
Revenue Growth
-1.80%48.91%45.26%30.09%-26.56%40.50%
Gross Profit
250.41M316.58M460.47M367.35M399.88M381.51M
Gross Margin
27.58%23.42%23.45%14.38%21.31%14.47%
Operating Income
-17.41M-19.88M14.18M23.94M-4.44M89.90M
Net Income
-37.60M-19.16M-113.04M-61.62M-534.51M-86.58M
EPS
----0.090.20
EPS Growth
-----78.05%121.83%
Forward PE
57.1944.3238.4013.6616.8824.64
Free Cash Flow
93.58M12.57M162.10M-48.00M98.41M-7.57M
No. Analysts
-----15
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High2.7B
Avg2.6B
Low2.6B

Revenue Growth

Revenue Growth202620272028
High
42.3%
Avg
40.5%
Low
36.5%

EPS Forecast

EPS202620272028
High0.27
Avg0.20
Low0.10

EPS Growth

EPS Growth202620272028
High
199.3%
Avg
121.8%
Low
11.1%